<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335359">
  <stage>Registered</stage>
  <submitdate>19/04/2010</submitdate>
  <approvaldate>21/04/2010</approvaldate>
  <actrnumber>ACTRN12610000322033</actrnumber>
  <trial_identification>
    <studytitle>The role of vitamin D in the treatment of nerve pain in diabetes</studytitle>
    <scientifictitle>Vitamin D as an analgesic for neuropathic pain in type 2 diabetes</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Neuropathic pain in type 2 diabetes</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Intramuscular vitamin D injection (300,000 units) at baseline</interventions>
    <comparator>Placebo injection with normal saline at baseline</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Pain scores on questionnaires (visual analogue scale, McGill short form pain questionnaire)</outcome>
      <timepoint>baseline and at 3 months and 6 months following randomisation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life (SF-36)</outcome>
      <timepoint>Baseline and 3 months and 6 months following randomisation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in severity of neuropathy on clinical examination and by biothesiometry.</outcome>
      <timepoint>Baseline and 3 months and 6 months after randomisation</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with type 2 diabetes and with painful neuropathy with a serum 25-hydroxyvitamin D level of less than 50 nmol/L</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients with type 1 or secondary diabetes, hypercalcaemia or renal stone</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Eligible patients are recruited from hospital clinics. Patients are randomized to vitamin D or placebo injection by a computer randomization program.</concealment>
    <sequence>Computer randomization program</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2 / Phase 3</phase>
    <anticipatedstartdate>1/04/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>2010</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>St Vincent's Hospital</primarysponsorname>
    <primarysponsoraddress>390 Victoria Street, Darlinghurst
NSW 2010</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Novo Nordisk Pharmaceuticals Pty. Ltd</fundingname>
      <fundingaddress>Level 3
21 Solent Circuit
BAULKHAM HILLS NSW 2153</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Concord Repatriation General Hospital</sponsorname>
      <sponsoraddress>Concord Repatriation General Hospital	
Hospital Rd, Concord NSW 2139</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>Garvan Institute of Medical Research</sponsorname>
      <sponsoraddress>384 Victoria Street
Darlinghurst
New South Wales 2010</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Vitamin D deficiency is common amongst people with type 2 diabetes. People with type 2 diabetes frequently develop painful neuropathy ("nerve pain" especially in the feet). The study hypothesis is that vitamin D supplementation may improve symptoms of nerve pain. The study is therefore designed to investigate the impact of vitamin D supplementation on nerve pain in people with type 2 diabetes</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St Vincent's Hospital Human Research Ethics Committee</ethicname>
      <ethicaddress>St Vincent's Hospital
390 Victoria Street, Darlinghurst
NSW 2010</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Paul Lee</name>
      <address>Department of Endocrinology
Garvan Institute of Medical Research
384 Victoria Street
Darlinghurst
New South Wales 2010</address>
      <phone>+61 2 9295 8486</phone>
      <fax>+61 2 9295 8481</fax>
      <email>p.lee@garvan.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Paul Lee</name>
      <address>Department of Endocrinology
Garvan Institute of Medical Research
384 Victoria Street
Darlinghurst
New South Wales 2010</address>
      <phone>+61 2 9295 8486</phone>
      <fax>+61 2 9295 8481</fax>
      <email>p.lee@garvan.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Paul Lee</name>
      <address>Department of Endocrinology
Garvan Institute of Medical Research
384 Victoria Street
Darlinghurst
New South Wales 2010</address>
      <phone>+61 2 9295 8486</phone>
      <fax>+61 2 9295 8481</fax>
      <email>p.lee@garvan.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>